TY - JOUR T1 - Death Receptor 6 as a Prognostic Marker in Low-grade Glioma JF - Anticancer Research JO - Anticancer Res SP - 1237 LP - 1245 DO - 10.21873/anticanres.15591 VL - 42 IS - 3 AU - SARAH K. STEGMANN AU - SASKIA KUHL AU - NAM GYU IM AU - DANG THUY DIEM-DINH AU - LUKAS GOERTZ AU - ROLAND GOLDBRUNNER AU - MARCO TIMMER Y1 - 2022/03/01 UR - http://ar.iiarjournals.org/content/42/3/1237.abstract N2 - Background/Aim: Low-grade gliomas (LGG) are heterogenous tumours, causing variable survivals in patients. Identifying molecular markers for a more accurate prognosis is, therefore, important. Since death receptor 6 (DR6) is up-regulated in gliomas and shows an aberrant signalling network, we tested its suitability as a prognostic marker. Materials and Methods: DR6 was investigated in patient samples via PCR and western blot. Clinical data were analysed and compared to The Cancer Genome Atlas (TCGA) ‘brain lower grade glioma’ dataset. Results: DR6 was found to be enhanced in LGG and its expression increased in recurrent LGG. The receptor showed a protective effect in primary LGG with a significantly elongated progression-free survival that was confirmed in the TCGA study. This effect was reversed in relapsed LGG in which cases with high DR6 expression reveal a shorter overall survival. Conclusion: DR6 is an interesting candidate for further studies regarding its effect as a prognostic marker, playing an opposing role in primary and relapsed LGG. ER -